|
22 Companies |
|
13 Products |
|
13 Products |
|
29 Mechanisms of Action |
|
3 Trials |
|
142 News |
|
| «123» |
- Trial completion: Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=6, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed
- Biomarker: Biomarkers in Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - Jun 4, 2014
P2, N=120, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- | New P1/2 trial: Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) (clinicaltrials.gov) - May 29, 2014
P1/2, N=15, Recruiting, Sponsor: TransDerm, Inc.
- linsitinib (ASP7487) / VasaraGen
Enrollment change, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - May 26, 2014
P2, N=20, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=40 --> 20
- Trial primary completion date: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
N=40 --> 20 Trial primary completion date: Jan 2015 --> May 2014
- Trial completion date: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial primary completion date: Jan 2015 --> May 2014 Trial completion date: Jan 2015 --> May 2014
- Trial completion: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial completion date: Jan 2015 --> May 2014 Recruiting --> Completed
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P2 trial: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 13, 2014
P2, N=120, Not yet recruiting, Sponsor: Bayer
- Trial primary completion date: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) (clinicaltrials.gov) - May 5, 2014
P2, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed Trial primary completion date: May 2012 --> Jul 2013
- Trial completion date: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) (clinicaltrials.gov) - May 5, 2014
P2, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Trial primary completion date: May 2012 --> Jul 2013 Trial completion date: May 2012 --> Jul 2013
- Trial completion: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) (clinicaltrials.gov) - May 5, 2014
P2, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Trial completion date: May 2012 --> Jul 2013 Recruiting --> Completed
- ||| Enrollment open: ECP-015: Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=150, Recruiting, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Apr 13, 2014
P2, N=23, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- Trial withdrawal: Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- Trial withdrawal: Optical Frequency Domain Imaging (OFDI) in Dermatology (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Recruiting --> Withdrawn Not yet recruiting --> Withdrawn
- Enrollment change: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Mar 28, 2014
P=N/A, N=1335, Completed, Sponsor: National Institute on Aging (NIA)
Not yet recruiting --> Withdrawn N=1835 --> 1335
- recombinant ectodysplasin A1 (APO200) / Onxeo, Pierre Fabre
Enrollment open: ECP-002e: Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002 (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=10, Recruiting, Sponsor: Edimer Pharmaceuticals
N=1835 --> 1335 Not yet recruiting --> Recruiting
- linsitinib (ASP7487) / VasaraGen
Enrollment closed, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 16, 2014
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P1 trial: Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC) (clinicaltrials.gov) - Feb 5, 2014
P1, N=15, Recruiting, Sponsor: Stanford University
- Enrollment change: Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=38, Completed, Sponsor: University Hospital Erlangen
Recruiting --> Active, not recruiting N=48 --> 38
- | Trial completion: Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=38, Completed, Sponsor: University Hospital Erlangen
N=48 --> 38 Recruiting --> Completed
- Trial completion: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=1335, Completed, Sponsor: National Institute on Aging (NIA)
Recruiting --> Completed Recruiting --> Completed
- Trial completion, Preclinical: Role of Pseudogene in Incontinentia Pigmenti, and Its Potential Treatment (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=50, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Completed Recruiting --> Completed
- Clinical: Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=5, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- Enrollment change: Phenotypic Properties in Individuals Affected With XLHED (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=30, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed N=150 --> 30
- | Trial completion: Phenotypic Properties in Individuals Affected With XLHED (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=30, Completed, Sponsor: Edimer Pharmaceuticals
N=150 --> 30 Recruiting --> Completed
- Trial completion: Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=10, Completed, Sponsor: Stanford University
Recruiting --> Completed Recruiting --> Completed
- recombinant ectodysplasin A1 (APO200) / Onxeo, Pierre Fabre
Trial completion: A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200 (clinicaltrials.gov) - Nov 24, 2013
P1, N=6, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- Trial termination: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Nov 19, 2013
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
Recruiting --> Completed Active, not recruiting --> Terminated
- Enrollment closed: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=3800, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- Enrollment open: Treatment of Nevus Flammeus With Alexandrite Laser (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=20, Recruiting, Sponsor: Bispebjerg Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment change: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Oct 3, 2013
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
Not yet recruiting --> Recruiting N=21 --> 1
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion: The Effects of Aldara as an Adjunct to Laser Treatment (clinicaltrials.gov) - Aug 11, 2013
P2, N=20, Completed, Sponsor: University of Kentucky
N=21 --> 1 Recruiting --> Completed
- New P1 trial: Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jul 23, 2013
P1, N=6, Completed, Sponsor: Royan Institute
- Trial completion: Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jul 23, 2013
P1, N=6, Completed, Sponsor: Royan Institute
Recruiting --> Completed Not yet recruiting --> Completed
- | lenalidomide / Generic mfg.
Enrollment closed: LENAKAP: Lenalidomide in Kaposi Disease Associated With HIV Infection (clinicaltrials.gov) - Jul 16, 2013
P2, N=35, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination: Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=119, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Terminated
- Enrollment change: Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=119, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated N=600 --> 119
- ||| Trial completion: X-CORS: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey (clinicaltrials.gov) - Jul 6, 2013
P=N/A, N=500, Completed, Sponsor: Edimer Pharmaceuticals
N=600 --> 119 Recruiting --> Completed
- recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Enrollment open, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Jul 2, 2013
P2, N=6, Recruiting, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Recruiting
- timbetasin topical (RGN-137) / RegeneRx
Trial initiation date: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 6, 2013
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
Active, not recruiting --> Recruiting Initiation date: Jan 2005 --> Feb 2006
- Trial withdrawal: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 19, 2013
P=N/A, N=0, Withdrawn, Sponsor: Lotus Tissue Repair, Inc.
Initiation date: Jan 2005 --> Feb 2006 Not yet recruiting --> Withdrawn
- Biomarker, Trial termination: Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias (clinicaltrials.gov) - May 19, 2013
P=N/A, N=28, Terminated, Sponsor: Duke University
Not yet recruiting --> Withdrawn Recruiting --> Terminated
- Enrollment change: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 19, 2013
P=N/A, N=0, Withdrawn, Sponsor: Lotus Tissue Repair, Inc.
Recruiting --> Terminated N=80 --> 0
- Biomarker, Enrollment change: Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias (clinicaltrials.gov) - May 19, 2013
P=N/A, N=28, Terminated, Sponsor: Duke University
N=80 --> 0 N=300 --> 28
- Trial completion: The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) (clinicaltrials.gov) - May 12, 2013
P4, N=6, Completed, Sponsor: Maastricht University Medical Center
N=300 --> 28 Enrolling by invitation --> Completed
- Trial termination: Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage (clinicaltrials.gov) - Apr 10, 2013
P0, N=7, Terminated, Sponsor: Healthpoint
Enrolling by invitation --> Completed Suspended --> Terminated; Business decision
- recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
New P2 trial, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Jan 23, 2013
P2, N=6, Recruiting, Sponsor: Edimer Pharmaceuticals
- Enrollment change: Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=36, Completed, Sponsor: Edimer Pharmaceuticals
Suspended --> Terminated; Business decision N=150 --> 36